Arovella Therapeutics Ltd (ASX:ALA) CEO Michael Baker updates on iNKT cell therapy platform human clinical trial progress

Australian biotechnology company Arovella Therapeutics Ltd (ASX: ALA) CEO Michael Baker updates JustStocks Video on the first-in-human clinical trial milestone for its iNKT cell therapy platform for blood cancers. Mr. Baker said that Arovella’s technology provides key advantages over CAR-T cell therapies. With the potential to be applied to both blood cancers and solid tumours. The company expects to achieve several critical milestones including manufacturing clinical batches of ALA-101 for phase I clinical trials with the study expected to get underway before the end of the year.

Articles of Interest